Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

OVERVIEW

Neuropsychiatric symptoms are common non-motor manifestations of patients with Parkinson's disease (PD) that worsen the cognitive progression of the disease and represent a major clinical challenge. Evidence suggests that more than 60% of PD patients have one or more psychiatric symptoms, yet they are often under-recognized in clinical practice. Even when recognized by healthcare providers, managing patients with these symptoms can be challenging due to the complexity of their medication regimens, unmet treatment needs, potential adverse events, drug-drug interactions (DDIs), and possible worsening of both motor and non-motor symptoms. Psychiatric pharmacist and psychiatric nurse specialists serve on the frontline of care and are uniquely positioned to play an essential role in the assessment of neuropsychiatric manifestations of PD, their treatment and management, and the delivery of supportive care to both patients and caregivers. Through interactive case-based presentations and expert discussion based on an archived webcast, this activity will review current and novel therapies for neuropsychiatric symptoms of patients with PD as well as strategies to manage their adverse events and DDIs. This webcast archive provides case-based presentations and expert discussion on current and novel therapies for neuropsychiatric symptoms of patients with PD, strategies to manage their adverse events and DDIs, and best practices in psychiatric pharmacist and nurse collaboration.

GOAL

The goal of this activity is to provide psychiatric pharmacists with the most up-to-date treatment strategies and to highlight the importance of psychiatric pharmacist and nurse collaboration in order to optimize management and improve outcomes for PD patients experiencing neuropsychiatric symptoms.

TARGET AUDIENCE

This activity is designed to meet the educational needs of pharmacists nationwide. No prerequisites required.

LEARNING OBJECTIVES

Upon the conclusion of this activity, the participant should be able to:

• RECOGNIZE the prevalence of neuropsychiatric symptoms in PD and their impact on disease burden.
• EVALUATE current and novel treatment options for the various neuropsychiatric symptoms.
• DISCUSS the role of psychiatric nurses and pharmacists in managing the neuropsychiatric symptoms of PD.
• ASSESS strategies to minimize the impact adverse events and DDIs have on patient outcomes.

CONTINUING EDUCATION INFORMATION

Pharmacist Credit:

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This enduring material provides 1.5 contact hours of knowledge-based credit (0.15 CEUs) from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-9999-17-033-H01-P.

NABP e-PROFILE ID NUMBER: Your CE credits will be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

Type of Activity: Knowledge

Published: April 8, 2017
Expires: April 8, 2018

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes

PARTICIPATING FACULTY

Jack J. Chen, PharmD, FASCP, FCCP, BCPS, BCGP
Chair and Professor – Department of Pharmacy Practice 
College of Pharmacy 
Marshall B. Ketchum University
Fullerton, California
Dr Chen reports serving on the speaker's bureau for ACADIA Pharmaceuticals Inc.

Dawn M. Vanderhoef, PhD, DNP, PMHNP-BC, FAANP
Assistant Professor and Academic Director, PMHNP Program
Assistant Professor of Psychiatry 
Vanderbilt University School of Nursing
Nashville, Tennessee
Dr Vanderhoef reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

The planners and managers have nothing to disclose related to the content of this CE activity. CPNP Executive Director, Brenda Schimenti, Medical Director, Ankita Patel, PharmD, and Senior Medical Editor, Lisa Mangione, all have nothing to disclose related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). Dr Chen's presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: Anti-epileptics for dementia symptoms, atypical antipsychotics for dementia symptoms, selective serotonin reuptake inhibitors for agitation, donepezil, galantamine, and memantine for PD dementia, pramipexole for depression, aripiprazole, clozapine, olanzapine, quetiapine, risperidone for hallucinations and delusions in PD, and trazadone for insomnia. The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

FAIR BALANCE AND INTEGRITY STATEMENT

It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (eg, their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.

ACTIVITY INSTRUCTIONS AND HOW TO EARN CREDIT

The following is an archived webcast activity, comprised of synced slides with audio, designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, the archived webcast, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.

Participants must complete the activity as described above. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5

TABLE OF CONTENTS

Preassessment and Activity Overview

Burden of Neuropsychiatric Symptoms in PD
Dawn M. Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

Managing Neuropsychiatric Symptoms: Current Treatment Landscape
Jack J. Chen, PharmD, FASCP, FCCP, BCPS, BCGP

Role of Pharmacist and Nurse Neuropsychiatric Specialists
Jack J. Chen, PharmD, FASCP, FCCP, BCPS, BCGP, and Dawn M. Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

Conclusions and Postassessment

What you are about to see is a previously recorded live webcast.
Please note that only "home study" credit will be awarded for participating in this archived presentation.
No "live" credits are available.